Atea Pharmaceuticals Highlights Strategic Priorities for 2023
January 09, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
Enrollment Progresses in SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 with Interim Analysis Expected 2H23 Proof-of-Concept...
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
MamaMancini’s Appoints Meghan Henson to Board of Directors
December 19, 2022 08:31 ET
|
MamaMancini's Holdings, Inc.
Seasoned Human Resources Executive Brings 20+ Years of Experience to the Board of Directors EAST RUTHERFORD, NJ, Dec. 19, 2022 (GLOBE NEWSWIRE) -- MamaMancini's Holdings, Inc. (NASDAQ: MMMB), a...
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
November 29, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of...
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Crawford Thomas Recruiting Named to Inc.’s Power Partner Awards
November 16, 2022 11:28 ET
|
Crawford Thomas Recruiting
ORLANDO, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Crawford Thomas Recruiting, the leading nationwide recruiting and staffing firm, announced it has been honored in Inc. Business Media’s inaugural...
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 08, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief...
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:05 ET
|
Atea Pharmaceuticals, Inc.
Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022 Completion of Patient Enrollment...
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
November 03, 2022 07:00 ET
|
Atea Pharmaceuticals, Inc.
Safety and pharmacokinetic data in healthy volunteers support ongoing clinical development AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development with a Fast Track...
Leading PR and Marketing Agency ÜberStrategist Receives Inc.’s Inaugural Power Partner Award - Celebrating Companies That Help Clients Win
November 01, 2022 07:00 ET
|
UberStrategist
ÜberStrategist Joins 252 Top Firms that Support Nation’s Entrepreneurs and Start-Ups, Based on Measurable Commitment, Reliability, Trust, Creativity, Supportiveness, and Key Virtues that Offer Value...